Bifemelane: Difference between revisions
No edit summary |
m (Protected "Bifemelane": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite))) |
(No difference)
|
Latest revision as of 18:08, 18 August 2015
Clinical data | |
---|---|
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
E number | {{#property:P628}} |
ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
Chemical and physical data | |
Formula | C18H23NO |
Molar mass | 269.381 g/mol |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
WikiDoc Resources for Bifemelane |
Articles |
---|
Most recent articles on Bifemelane |
Media |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on Bifemelane at Clinical Trials.gov Clinical Trials on Bifemelane at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on Bifemelane
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on Bifemelane Discussion groups on Bifemelane Patient Handouts on Bifemelane Directions to Hospitals Treating Bifemelane Risk calculators and risk factors for Bifemelane
|
Healthcare Provider Resources |
Causes & Risk Factors for Bifemelane |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Bifemelane (Alnert, Celeport) is a pharmaceutical drug used in the treatment of senile dementia in Japan.[1] It has nootropic, neuroprotective, and antidepressant effects, and acts through the cholinergic system in the brain.[2][3][4] Bifemelane is also useful for the treatment of glaucoma.[5]
References
- ↑ David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. p. 265. ISBN 0-412-46630-9.
- ↑ Kondo, Y; Ogawa, N; Asanuma, M; Matsuura, K; Nishibayashi, K; Iwata, E (1996). "Preventive effects of bifemelane hydrochloride on decreased levels of muscarinic acetylcholine receptor and its mRNA in a rat model of chronic cerebral hypoperfusion". Neuroscience research. 24 (4): 409–14. doi:10.1016/0168-0102(95)01017-3. PMID 8861111.
- ↑ Egashira, T; Takayama, F; Yamanaka, Y (1996). "Effects of bifemelane on muscarinic receptors and choline acetyltransferase in the brains of aged rats following chronic cerebral hypoperfusion induced by permanent occlusion of bilateral carotid arteries". Japanese journal of pharmacology. 72 (1): 57–65. doi:10.1254/jjp.72.57. PMID 8902600.
- ↑ Moryl E, Danysz W, Quack G (June 1993). "Potential antidepressive properties of amantadine, memantine and bifemelane". Pharmacology & Toxicology. 72 (6): 394–7. doi:10.1111/j.1600-0773.1993.tb01351.x. PMID 8361950.
- ↑ Shigemitsu, T; Majima, Y (1996). "Use of bifemelane hydrochloride in improving and maintaining the visual field of patients with glaucoma". Clinical therapeutics. 18 (1): 106–13. doi:10.1016/S0149-2918(96)80183-4. PMID 8851457.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Template:drugs.com link with non-standard subpage
- Articles with changed EBI identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Drugs with no legal status
- Drugboxes which contain changes to verified fields
- Nootropics
- Phenol ethers
- Amines
- Drug